問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Yang-Ming University Hospital (在職)

Division of General Internal Medicine

Division of Cardiovascular Diseases

國立陽明交通大學附設醫院

Division of Cardiovascular Diseases

更新時間：2023-09-19

廖照峰
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

6Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

廖照峰

List

12Cases

2025-07-01 - 2030-12-31

Active

  • Condition/Disease

  • Test Drug

Participate Sites
23Sites

Recruiting23Sites

2024-03-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
21Sites

Not yet recruiting11Sites

Recruiting9Sites

2023-03-01 - 2027-02-28

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting16Sites

2024-02-27 - 2030-01-27

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting1Sites

Suspended15Sites

2026-01-01 - 2031-09-18

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

2025-06-02 - 2029-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2020-06-15 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting4Sites

Recruiting8Sites

2023-03-01 - 2027-02-28

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting16Sites

2014-11-01 - 2019-05-31

Phase III

A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction

  • Condition/Disease

    Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction

  • Test Drug

    LCZ696

Participate Sites
9Sites

Terminated9Sites

2016-11-01 - 2021-04-10

Phase III

A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction

  • Condition/Disease

    acute myocardial infarction

  • Test Drug

    LCZ696

Participate Sites
9Sites

Not yet recruiting2Sites

Terminated7Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB